Dicynone pills 250mg 100pcs

Composition

Active ingredients:

ethamzylate 250 mg. Auxiliary substances:

citric acid anhydrous,

corn starch,

povidone K 25,

magnesium stearate,

lactose.

Pharmacological action

Dicynone is a hemostatic, antihemorrhagic and angioprotective substance, normalizes the permeability of the vascular wall, improves microcirculation.

It stimulates the formation of platelets and their release from the bone marrow. The hemostatic effect is due to the activation of thromboplastin formation at the site of damage to small vessels and a decrease in the formation of prostacyclin PgI2 in the vascular endothelium,

Dicynone increases platelet adhesion and aggregation, which ultimately leads to a stop or decrease in bleeding. Increases the rate of primary blood clot formation and increases its retraction, practically does not affect the concentration of fibrinogen and prothrombin time.

Doses of more than 2-10 mg / kg do not lead to a greater effect. With repeated injections, thrombosis increases. The angioprotective effect of Dicynone is associated with its effect on the endothelium of capillaries and the main substances of interendothelial spaces.

Having antihyaluronidase activity and stabilizing ascorbic acid, it prevents the destruction and promotes the formation of mucopolysaccharides with a large molecular weight in the capillary wall, increases capillary resistance, reduces their fragility, and normalizes permeability under pathological conditions. Reduces the release of fluid and diapedesis of blood elements from the vascular bed, improves microcirculation.

This angioprotective effect is manifested in the treatment of various diseases associated with primary or secondary disorders of the microcirculation process. It does not have hypercoagulable properties, does not contribute to thrombosis, and does not have a vasoconstrictive effect. Restores pathologically altered bleeding time. It does not affect the normal parameters of the hemostatic system.

Dicynone practically does not affect the composition of peripheral blood, its proteins and lipoproteins. Slightly increases the content of fibrinogen. The rate of erythrocyte sedimentation may decrease slightly. In addition, it normalizes or reduces pathologically increased capillary permeability and fragility.

Indications

Prevention and treatment of capillary bleeding of various etiologies:

• during and after surgical operations on all well-vascularized tissues in otorhinolaryngology, gynecology, obstetrics, urology, dentistry, ophthalmology and plastic surgery;
• hematuria, metrorrhagia, primary menorrhagia, menorrhagia in women with intrauterine devices, epistaxis, bleeding gums;
• diabetic microangiopathy (diabetic hemorrhagic retinopathy, repeated hemorrhages in the retina, hemophthalmus);
• intestinal and pulmonary hemorrhage;
• bleeding in diabetes;
• intracranial hemorrhage in neonates and premature infants.

Contraindications

• acute porphyria;
• hemoblastosis in children (lymphoblastic and myeloblastic leukemia, osteosarcoma);
• thrombosis;
• thromboembolism;
• bleeding caused
• by anticoagulants hypersensitivity to the components of the drug and sodium sulfite;
• hypersensitivity to sodium sulfite (solution for intravenous and intramuscular use).

With caution, the drug should be prescribed for thrombosis, a history of thromboembolism, bleeding on the background of an overdose of anticoagulants.

Side effects

From the central nervous system and peripheral nervous system:  headache, dizziness, paresthesia of the lower extremities.

From the digestive system:  nausea, heartburn, heaviness in the epigastric region.

Other services:  allergic reactions, hyperemia of the facial skin, decreased systolic blood pressure.

Interaction

use of dextrans at a dose of 10 mg/kg of body weight 1 hour before use prevents their antiplatelet effect. Dicynone use after dextran use has no hemostatic effect.

It can be combined with aminocaproic acid and menadione sodium bisulfite.

Pharmaceutical interaction

Pharmacologically incompatible (in one syringe) with other drugs.

Incompatible with sodium bicarbonate solution for injection and sodium lactate solution.

How to take, course of use and dosage

The optimal daily dose for adults is 10-20 mg / kg of body weight, divided into 3-4 doses. In most cases, a single dose is 250-500 mg 3-4 times / day. In exceptional cases, a single dose can be increased to 750 mg 3-4 times / day.

When menorrhagia is prescribed 750-1000 mg / day, starting from the 5th day of the expected menstruation to the 5th day of the next menstrual cycle.

In the postoperative period, the drug is prescribed in a single dose of 250-500 mg every 6 hours until the risk of bleeding disappears.

Children are prescribed a daily dose of 10-15 mg / kg in 3-4 doses.

Overdose

Data on overdose of Dicynone are not available.

Special instructions

Other causes of bleeding should be excluded before starting treatment.

1 tablet of Dicynone contains 60.5 mg of lactose (the maximum daily dose of lactose should not exceed 5 g). Do not prescribe the drug to patients with congenital glucose intolerance, lapp lactase deficiency (lactase deficiency in some peoples of the North) or glucose-galactose malabsorption syndrome.

Effects on the ability to drive motor vehicles and operate mechanisms Do not require special precautions.

Composition

Tablet Form of production

Storage conditions

In a dark place, at a temperature not exceeding 25 °C.

Shelf life

5 years

Active ingredient

Ethamzylate

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as prescribed by a doctor, Children as prescribed by a doctor, Pregnant women as prescribed by a doctor

Indications

Nosebleed, Bleed